Call Start: 16:30 January 1, 0000 5:18 PM ET
GeoVax Labs, Inc (NASDAQ:GOVX)
Q1 2022 Earnings Conference Call
April 27, 2022, 4:30 PM ET
Company Participants
David A. Dodd – Chairman and Chief Executive Officer
Mark Reynolds – Chief Financial Officer
Mark Newman – Chief Scientific Officer
John W. Sharkey – Head, Business Development
Kelly McKee – Chief Medical Officer
Jules Abraham – CORE, Investor Relations
Conference Call Participants
Joanne Lee – Maxim Group
Jeffrey Kraws – Crystal Research Associates, LLC
Michael Okunewitch – Maxim Group
Operator
Good afternoon and welcome everyone to the GeoVax first-quarter 2022, Corporate Update Call. I am Chuck with course call, and I will facilitate today's call. With me are David Dodd, Chairman and CEO, Mr. Mark Reynolds, Chief Financial Officer, Mr. Mark Newman, PhD, Chief Scientific Officer, and Mr. John Sharkey, PhD, Head Business Development. All participants will be in a listen-only mode. [Operator Instructions]. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference over to Jules Abraham of CORE IR, who will provide a forward-looking statement regarding this call and information herein, please go ahead, sir.
Jules Abraham
Thank you, Chuck and good afternoon, everyone. Please note the following, certain statements in this presentation may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner. Whether GeoVax's vaccines will be safe for human use. Whether GeoVax's vaccines will effectively prevent targeted infections in humans. Whether GeoVax's vaccines will receive regulatory approvals necessary to be licensed and marketed.
Whether GeoVax raises require capital to complete vaccine development. There is development of competitive products that maybe more effective or easier to use in GeoVax's products. Whether GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission, including those set forth as risk factors in GeoVax's Form 10-K. It is now my pleasure to introduce the Chairman and CEO of GeoVax, David Dodd. David.